KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Other Working Capital Changes: 2009-2024

Historic Other Working Capital Changes for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to -$354.1 million.

  • Novavax's Other Working Capital Changes fell 131.16% to -$11.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$621.5 million, marking a year-over-year decrease of 339.87%. This contributed to the annual value of -$354.1 million for FY2024, which is 200.92% down from last year.
  • According to the latest figures from FY2024, Novavax's Other Working Capital Changes is -$354.1 million, which was down 200.92% from $350.9 million recorded in FY2023.
  • Over the past 5 years, Novavax's Other Working Capital Changes peaked at $1.3 billion during FY2021, and registered a low of -$1.0 billion during FY2022.
  • Over the past 3 years, Novavax's median Other Working Capital Changes value was -$354.1 million (recorded in 2024), while the average stood at -$349.7 million.
  • As far as peak fluctuations go, Novavax's Other Working Capital Changes skyrocketed by 5,173.69% in 2020, and later tumbled by 200.92% in 2024.
  • Novavax's Other Working Capital Changes (Yearly) stood at $422.7 million in 2020, then soared by 213.60% to $1.3 billion in 2021, then plummeted by 178.90% to -$1.0 billion in 2022, then soared by 133.55% to $350.9 million in 2023, then slumped by 200.92% to -$354.1 million in 2024.